Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab and tuvonralimab + nab-paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
QL1706 + nab-paclitaxel + bevacizumab (also known as iparomlimab and tuvonralimab + nab-paclitaxel + bevacizumab) is an investigational combination regimen being evaluated for the treatment of various solid tumors, including recurrent or metastatic triple-negative breast cancer (TNBC), platinum-resistant recurrent ovarian cancer, and non-small cell lung cancer (NSCLC). The regimen combines QL1706 (iparomlimab and tuvonralimab)—a first-in-class bifunctional MabPair product containing a mixture of anti-PD-1 IgG4 (iparomlimab) and anti-CTLA-4 IgG1 (tuvonralimab) monoclonal antibodies produced in a single cell line—with nab-paclitaxel (nanoparticle albumin-bound paclitaxel, a microtubule inhibitor) and bevacizumab (an anti-VEGF monoclonal antibody that inhibits angiogenesis). By simultaneously targeting the PD-1 and CTLA-4 immune checkpoints, inhibiting tumor angiogenesis, and delivering cytotoxic chemotherapy, the combination aims to achieve synergistic antitumor activity.
- Other names
- iparomlimab and tuvonralimab + albumin-bound paclitaxel + bevacizumabiparomlimab/tuvonralimab + nab-paclitaxel + bevacizumabQL1706 + nab-paclitaxel + bevacizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on iparomlimab and tuvonralimab + nab-paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab and tuvonralimab + nab-paclitaxel + bevacizumab.